Bacterial Conjunctivitis Market Growth Trajectory Through 2024-2033

Spread the love

The Bacterial Conjunctivitis Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Bacterial Conjunctivitis Market:

https://www.thebusinessresearchcompany.com/report/bacterial-conjunctivitis-global-market-report

According to The Business Research Company’s Bacterial Conjunctivitis Global Market Report 2024, The bacterial conjunctivitis market size has grown strongly in recent years. It will grow from $4.29 billion in 2023 to $4.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing incidence of bacterial infections, improved diagnostic capabilities, patient education and awareness programs, stringent regulatory framework, physician training and expertise..

The bacterial conjunctivitis market size is expected to see steady growth in the next few years. It will grow to $5.34 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to global population growth, rising urbanization and pollution, increased focus on preventive eye care, global health preparedness initiatives, expansion of teleophthalmology services, collaboration in research and development.. Major trends in the forecast period include innovation in drug delivery technologies, customization of treatment regimens, utilization of broad-spectrum antibiotics, introduction of adjunctive therapies, emphasis on patient education and prevention strategies..

The increasing prevalence of eye infections is expected to propel the growth of the bacterial conjunctivitis market going forward. An eye infection is a condition in which the eye is affected by the invasion and multiplication of harmful microorganisms such as bacteria, viruses, fungi, or parasites. It includes conjunctivitis, trachoma, and keratitis. Bacterial conjunctivitis is an eye infection caused by bacteria treated with prescribed medications, self-care techniques, and hygiene measures. For instance, in October 2022, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2021, approximately 69,000 people underwent surgery for the late and blinding stage of trachoma ( Eye bacterial infection), while 64.6 million people received treatment with antibiotics for trachoma. Furthermore, in October 2022, according to The BrightFocus Foundation, a US-based nonprofit organization, there were currently 80 million glaucoma sufferers globally, and by 2040, it is projected to rise to nearly 111 million. Therefore, the increasing prevalence of eye infections is driving the growth of the bacterial conjunctivitis market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13383&type=smp

The bacterial conjunctivitis market covered in this report is segmented –

1) By Types: Hyperacute Bacterial Conjunctivitis, Acute Bacterial Conjunctivitis, Chronic Bacterial Conjunctivitis

2) By Drug Class: Antibiotics, Fluoroquinolones, Aminoglycosides, Macrolides, Antihistamines, Corticosteroids, Other Drug Classes

3) By Route of Administration: Oral, Topical, Other Routes Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

Major companies operating in the bacterial conjunctivitis market are increasing their focus on developing innovative eye drops, such as broad-spectrum eye drops, to maximize their revenues in the market. Broad-spectrum eye drops are medications designed to treat various eye infections, including those caused by various bacteria. These eye drops contain antibiotics that are effective against a broad spectrum of bacteria rather than targeting a specific type. For instance, in June 2023, Harrow Health, a US-based pharmaceutical company, launched Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% in the US. Vigamox is a fluoroquinolone antibiotic eye drop used to treat bacterial conjunctivitis.

The bacterial conjunctivitis market report table of contents includes: